MannKind Corporation
Use of ultrarapid acting insulin
Last updated:
Abstract:
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Status:
Grant
Type:
Utility
Filling date:
16 Apr 2019
Issue date:
25 May 2021